University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute

NCT06852222 – A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of BLEXIMENIB, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy

Last modified: June 24, 2026
You are here:
  • Find a Clinical Trial
  • All Clinical Trials
  • NCT06852222 – A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of BLEXIMENIB, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.

Learn More

Tags:
Was this article helpful?
Dislike 0